Nocturnal Enuresis Medication Market Report 2026

The nocturnal enuresis medication market size has grown strongly in recent years. It will grow from $1.63 billion in 2025 to $1.74 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to high prevalence of pediatric nocturnal enuresis, widespread use of desmopressin, increased pediatric healthcare access, expansion of retail pharmacy networks, growing parental awareness.

The nocturnal enuresis medication market size is expected to see strong growth in the next few years. It will grow to $2.26 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to growth in pediatric urology care, rising demand for safer long-term therapies, advancements in drug formulations, increased diagnosis in adolescents and adults, expansion of online pharmacy access. Major trends in the forecast period include increasing use of desmopressin-based therapies, growing adoption of combination drug treatments, rising awareness of pediatric bedwetting management, expansion of extended-release formulations, increasing focus on long-term treatment safety.

The growing demand for personalized care is expected to drive the expansion of the nocturnal enuresis medication market in the coming years. Personalized care is a medical approach that customizes treatment and healthcare strategies based on an individual’s genetic profile, lifestyle, preferences, and specific health conditions, ensuring more targeted and effective outcomes. This demand is rising due to advancements in medical technology that enable healthcare providers to tailor treatments according to each patient’s genetics, lifestyle, and health conditions, resulting in more precise and effective care. Personalized care enhances nocturnal enuresis treatment by adapting therapy plans to an individual’s medical history, lifestyle, and underlying causes, thereby improving treatment effectiveness and adherence. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit organization, reported that the Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, up from 6 in 2022. Consequently, the increasing demand for personalized care is fueling the growth of the nocturnal enuresis medication market.

The rising healthcare expenditure is expected to drive the growth of the nocturnal enuresis medication market in the coming years. Healthcare expenditure refers to the total spending on medical services, products, and public health by individuals, governments, and organizations over a specific period. This increase is driven by factors such as the growing prevalence of chronic diseases, which require long-term management, ongoing treatment, and frequent medical interventions, resulting in higher costs for medications, healthcare services, and specialized care. Higher healthcare expenditure supports the nocturnal enuresis medication market by enabling greater investment in research, development, and access to advanced treatment options, thereby improving the availability and effectiveness of care for patients. For example, in January 2024, Peterson-KFF Health System Tracker, a U.S.-based non-profit data and analysis platform, projected that U.S. health spending would reach $4.9 trillion in 2024, up 5% from $4.67 trillion in 2023. Consequently, increasing healthcare expenditure is fueling the growth of the nocturnal enuresis medication market.

Leading companies in the nocturnal enuresis medication market are focusing on developing advanced solutions, such as orally disintegrating tablets (ODTs), to enhance ease of administration. Orally disintegrating tablets (ODTs) are solid dosage forms that dissolve or disintegrate rapidly in the mouth without the need for water, making them ideal for patients with swallowing difficulties. For example, in March 2024, Adalvo Limited, a Malta-based pharmaceutical company, launched desmopressin ODTs in Europe. Desmopressin ODT is specifically formulated for the treatment of primary nocturnal enuresis, offering a convenient and easy-to-administer option that quickly disintegrates in the mouth. This formulation is especially beneficial for pediatric and elderly patients, as well as those who have difficulty swallowing tablets. The launch underscores Adalvo’s commitment to providing high-quality, differentiated pharmaceutical products while improving patient access to essential therapies through strategic industry partnerships.

Major companies operating in the nocturnal enuresis medication market are Ferring Pharmaceuticals A/S, Serenity Pharmaceuticals LLC, Vantia Therapeutics Ltd., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Astellas Pharma Inc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., Mylan N.V., Sandoz Group AG, Endo International plc, Bausch Health Companies Inc., Hikma Pharmaceuticals PLC.

North America was the largest region in the nocturnal enuresis medication market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nocturnal enuresis medication market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nocturnal enuresis medication market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the nocturnal enuresis medication market by increasing the cost of imported active ingredients and finished formulations used in pediatric therapies. These impacts are most evident in pediatric drug segments across North America, Europe, and Asia Pacific, where reliance on global pharmaceutical sourcing remains high. Rising tariff related expenses have contributed to slight increases in retail drug prices and distribution costs. This has influenced pricing strategies and procurement planning across retail and hospital pharmacy channels. Positively, tariffs have supported local pharmaceutical manufacturing, expanded domestic production capacity, and improved long term supply stability.

The nocturnal enuresis medication market research report is one of a series of new reports that provides nocturnal enuresis medication market statistics, including nocturnal enuresis medication industry global market size, regional shares, competitors with a nocturnal enuresis medication market share, detailed nocturnal enuresis medication market segments, market trends and opportunities, and any further data you may need to thrive in the nocturnal enuresis medication industry. This nocturnal enuresis medication market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nocturnal enuresis medication refers to pharmaceutical treatments aimed at managing and reducing involuntary urination during sleep, commonly known as bedwetting, especially in children and occasionally in adults. These medications work by improving bladder control, decreasing overnight urine production, or modifying the body’s sleep response to a full bladder.

The main drug classes for nocturnal enuresis include desmopressin, imipramine, oxybutynin, combined pharmacotherapy, and antidepressants. Desmopressin is a synthetic hormone that reduces nighttime urine production and is commonly prescribed for bedwetting. It is used across different age groups, including children, adolescents, adults, and the elderly, and is available in various formulations such as tablets, liquid solutions, sprays, patches, and extended-release forms. These medications are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The nocturnal enuresis medication market consists of sales of fixed-dose combination drugs, nutraceuticals, and herbal supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.